MENLO PARK, CA – January 27, 2014 – AtheroMed, a developer of innovative catheter technologies for treating peripheral artery disease (PAD), today announced that it has received FDA clearance to market the Phoenix Atherectomy System®, which allows physicians to treat PAD with a low profile atherectomy catheter that continuously removes diseased material as it is debulked and does not require specialized capital equipment.
“Peripheral artery disease, especially lesions located below the knee, can be challenging to treat, even with currently available technologies,” said Dr. Thomas Davis, Director of the Cardiac Catheterization Lab and Director of Peripheral Interventions and Disease at St. John Hospital and Medical Center in Detroit, MI. “My experience with the Phoenix device during the EASE clinical study was extremely positive, and I am excited that the device is now available as it will allow me to debulk small vessels that I may not have been able to treat in the past.”
Read more: http://www.atheromedinc.com/atheromed-announces-fda-clearance-to-market-the-phoenix-atherectomy-system-for-treating-peripheral-artery-disease/
AtheroMed Announces FDA Clearance to Market the Phoenix Atherectomy System for Treating Peripheral Artery Disease